Assistant Professor of Medicine, Massachusetts General Hospital
Oncology
Dr. Lori J. Wirth, MD
|
|
Give Review
Dr. Lori J. Wirth is an expert in the field of Oncology. She researched medicine at Columbia University College of Physicians & Surgeons. Columbia University College of Physicians & Surgeons is a top medical college. Columbia University College of Physicians & Surgeons has a rank of 8 in research and a 52 in primary care Lori Wirth is also published. She has 32 publications published. The lastest publication: "Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.' Lori J. Wirth is registered with Medicare and accepts Medicare payments.
Publications
- Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib.
- Lenvatinib versus placebo in radioiodine-refractory thyroid Cancer.
- Thyroid Carcinoma, version 2.2014.
- Chemotherapy for locally advanced and metastatic pulmonary carcinoid Tumors.
- Chemoprevention of Squamous Cell Carcinoma of the Head and Neck: No Time to Lose Momentum.
- Long-term survival after distant metastasis in patients with oropharyngeal Cancer.
- Mutation frequency in 15 common Cancer genes in high-risk head and neck squamous cell carcinoma (HNSCC).
- Case records of the Massachusetts General Hospital. Case 5-2013. A 52-year-old woman with a mass in the thyroid.
- Detection of novel actionable genetic changes in salivary duct Carcinoma helps direct patient treatment.
- Survival of a Patient with Anaplastic Thyroid Cancer Following Intensity-modulated Radiotherapy and Sunitinib - A Case Report.
- Cabozantinib in Medullary Thyroid Carcinoma: Time to Focus the Spotlight on This Rare Disease.
- Efficacy and Toxicity of Chemoradiotherapy Using Intensity-Modulated Radiotherapy for Unknown Primary of Head and Neck.
- Efficacy and toxicity of reirradiation using intensity-modulated radiotherapy for recurrent or second primary head and neck Cancer.
- Neoadjuvant treatment of unresectable medullary thyroid Cancer with sunitinib.
- Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid Cancer.
- Sequential therapy for the locally advanced larynx and hypopharynx Cancer subgroup in TAX 324: survival, surgery, and organ preservation.
- Decreased EBNA-1-specific CD8+ T Cells in patients with Epstein-Barr virus-associated nasopharyngeal carcinoma.
- Induction chemotherapy in locally advanced head and neck Cancer: a new standard of care?
- Dose to larynx predicts for swallowing complications after intensity-modulated radiotherapy.
- A pilot surrogate endpoint biomarker study of celecoxib in oral preMalignant lesions.
- A phase II study of gefitinib in patients with advanced thyroid Cancer.
- Glioblastoma in a patient with early-stage tonsil Cancer.
- Concurrent weekly docetaxel and concomitant boost radiation therapy in the treatment of locally advanced squamous cell Cancer of the head and neck.
- Dysphagia after sequential chemoradiation therapy for advanced head and neck Cancer.
- Examining the need for neck dissection in the era of chemoradiation therapy for advanced head and neck Cancer.
- Chemoradiotherapy for adenoid cystic Carcinoma: preliminary results of an organ sparing approach.
- Cetuximab and radiotherapy for head and neck Cancer.
- Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous Cell carcinoma of the head and neck.
- Organ preservation and treatment toxicity with induction chemotherapy followed by radiation therapy or chemoradiation for advanced laryngeal Cancer.
- Endoscopic management of hypopharyngeal stenosis after organ sparing therapy for head and neck Cancer.
- Induction docetaxel and carboplatin followed by weekly docetaxel and carboplatin with concurrent radiotherapy, then surgery in stage III non-small cell lung Cancer: a ...
Schools
Columbia University College of Physicians And Surgeons
New York Presbyterian Hospital
Dana Farber Cancer Institute
Procedures Preformed
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Basal Cell Carcinoma
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
Brigham and Women's Hospital -
New York Presbyterian Hospital -
Columbia University College of Physicians & Surgeons
Hospital
-
Massachusetts General Hospital
Drug Facts
| NPI NUMBER | 1750344008 | |
| NPPES Provider LastName | WIRTH | |
| NPPES Provider FirstName | LORI | |
| NPPES Provider ZIPCode | 02115 | |
| NPPES Provider State | MA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 179.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 11.0 | |
| Percent Opioid Claims | 6.15 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1750344008 |
| Last Name Of The Provider | WIRTH |
| First Name Of The Provider | LORI |
| View All |
Similar Doctors
|
|
Dr. Andrew S. Paulson, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Iain J. Webb, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sarah Schellhorn, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jason Luke, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniel C. Cho, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rochelle G. Scheib, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Zuzana Tothova, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Aymen Elfiky, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sigurdis Haraldsdottir, MD |